Dr. Marco Stief

"Bei Marco Stief merkt man, dass er die Branche einfach durch und durch kennt. Neben hervorragenden juristischen Kenntnissen, verfügt er über ein schnelles technisches Verständnis unserer sehr verschiedenen Produkte. Entscheidend für uns ist allerdings, dass er immer auch die langfristigen Konsequenzen im Blick hat, und den Markt sowie angrenzenden Rechtsbereiche sehr gut kennt. Dadurch ist es ihm möglich, auch kreative Lösungen zu entwickeln und unmittelbar auf Ebene der Geschäftsführung Lösungsansätze und Strategien zu besprechen."

– Legal 500 DE, 2023

"Marco Stief is highlighted by market sources as 'a trusted adviser and excellent litigator' who 'knows all the tricks' and has 'great experience in particular in pharma-related matters'"

– Who´s Who Legal, 2023

"With Marco Stief you can tell that he knows the industry through and through. In addition to excellent legal knowledge, he has a quick technical understanding of our very different products. What is decisive for us, however, is that he always keeps an eye on the long-term consequences and knows the market and related areas of law very well. This enables him to develop creative solutions and to discuss possible solutions and strategies directly at management level."

– Legal 500 EMEA, 2022

“'Excellent litigator' Marco Stief is described as 'experienced and knowledgeable' by peers for his work in the patent arena."

– Who's Who Legal, 2022

"Marco Stief stands out among peers for his in-depth patent knowledge and clear focus on pharmaceutical-related IP matters."

– Who's Who Legal, 2022

"Marco Stief is one of the leading individuals in Germany for patent strategy, particularly in the pharmaceutical field. Marco maintains one of the best Supplementary Protection Certificate practices in the country and is considered a thought leader in this space."

– IAM 300, 2022

“very experienced in pharma litigation, extraordinary knowledge of SPCs”

– JUVE Patent, 2021

"Heading up the legal department is seasoned attorney at law Marco Stief, who is equally proficient in litigation and licensing scenarios. Recent credits include acting in preliminary injunction proceedings on behalf of Fresenius against Eli Lilly."

– IAM Patent 1000, 2021

"Stief, der das Rechtsanwaltsteam leitet, gilt in der Branche als ausgewiesener Experte für Lizenzen u. Fragen rund um Verlängerungspatente für Arzneien (SPCs)."

– JUVE, 2021

"Marco Stief, who 'brings great technical understanding and a very outcome-oriented and practical approach to any project, is always very responsive and has a brilliant strategic mind'. 'He is very convincing in court and always thinks one step ahead.'"

– IAM Patent 1000, 2020